An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
VERDICT
The label
Markdown
read at $7.96
Novavax, Inc. holds its Markdown at $7.96.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-12
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 19 days
Price
$7.96
Valuation
N/A trailing · -12.97 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.42
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$7.96
N/A P/E · -12.97 fwd
Our fair value
$15.92
100% discount
Analyst target (avg)
$16.02
+101% to current
Target low $7.00Analyst target rangeTarget high $25.00
▲ current $7.96 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$7.96
you are here
Conservative
$7.00
-12%
Analyst avg
$16.02
+101%
Our fair value
$15.92
+100%
Analyst high
$25.00
+214%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-76.30%
Profit margin
-59.87%
Analyst consensus
Buy · 9 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its interest-bearing securities. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 21.1% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashInterest-bearing cash and securities are 42.0% of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is 29.5% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
COVID vaccine sales have fallen off a cliff
Picture a company that once rode the pandemic wave now watching orders vanish almost overnight. Novavax still sells its Nuvaxovid shot and a malaria vaccine candidate, yet revenue has dropped 79 percent and the firm continues to post a 15 percent loss margin. Analysts see a path to $16 while our fair value sits at $16.02, but the opportunity rating stays at none because shrinking demand and a negative forward multiple tell a clearer story than any target price.
The business model depends on winning fresh contracts for infectious disease shots in a market that has moved on from emergency COVID buying. Ethical screens clear the name, yet unknown competitive protection and the speed of the revenue collapse leave little room for steady returns. A low share price next to distant analyst hopes does not change the fact that peak pandemic earnings are gone.
High volatility around government tenders and the risk that new products arrive too late remain the real concerns here. The margin of safety looks wide on paper, but a contracting top line makes any recovery uncertain at best. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in NVAX's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
NVAX trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $14. Entered 2026-08-07 · Distribution
JOURNAL
The dated journal · newest first, never edited
2026-08-07Distribution · changed$8.21-7.5%Entry 4
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $14.
2026-07-18Markup$8.88+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (9 analysts) rates it none, with a mean price target of $14.
2026-07-03Markup$8.88+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$8.88Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$9.50
-10.3%
·
$897
-10.3%
2 months
$8.12
+4.9%
·
$1,049
+4.9%
3 months
$10.30
-17.3%
·
$827
-17.3%
6 months
$6.69
+27.4%
·
$1,274
+27.4%
1 year
$7.20
+18.3%
·
$1,183
+18.3%
2 years
$16.01
-46.8%
·
$532
-46.8%
3 years
$7.47
+14.1%
·
$1,141
+14.1%
5 years
$209.68
-95.9%
·
$41
-95.9%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever NVAX does next, these words stay.
Novavax, Inc. · NVAX · Markdown · $7.96
Recorded 2026-08-12 · before the outcome · scored mechanically
